Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 4/20 | 0.44 |
| ▸ | CNR1 | P21554 | 7/20 | 0.43 |
| ▸ | CNR2 | P34972 | 6/20 | 0.43 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CASP2 | P42575 | 1/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.39 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19698263 | 0.87 | TSHR (0.38) | FAAHCNR1CNR2DNM1GAA | |
| SCHEMBL19698259 | 0.87 | TSHR (0.38) | FAAHCNR1CNR2DNM1GAA | |
| SCHEMBL17740102 | 0.86 | FAAH (0.47) | FAAHCNR1CNR2DNM1GAA | |
| SCHEMBL19698297 | 0.85 | TSHR (0.39) | FAAHCNR1CNR2GAATSHR | |
| SCHEMBL19698299 | 0.85 | TSHR (0.39) | FAAHCNR1CNR2GAATSHR | |
| SCHEMBL19698320 | 0.85 | TSHR (0.40) | FAAHCNR1CNR2DNM1GAA | |
| SCHEMBL19698318 | 0.85 | TSHR (0.40) | FAAHCNR1CNR2DNM1GAA | |
| SCHEMBL19703619 | 0.84 | FAAH (0.45) | FAAHCNR1CNR2DNM1CASP2 | |
| SCHEMBL19698324 | 0.83 | TSHR (0.41) | FAAHCNR1CNR2DNM1CASP2 | |
| SCHEMBL19698315 | 0.83 | TSHR (0.41) | FAAHCNR1CNR2DNM1CASP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355731-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355731-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | RNGTT, RNASE1, RNMT | FAAH 3895/4885CNR1 4623/4885CNR2 4749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.